Bedrijfsoverzicht
VivoSim Labs, Inc. operates as a specialized pharmaceutical and biotechnology services firm that focuses on evaluating drug candidates and approved medications using three-dimensional human tissue models specifically for the liver and intestine. Within the broader Healthcare sector, the company functions within the Biotechnology industry, providing a distinct methodology known as New Approach Methodologies (NAM) to deliver critical liver and intestinal toxicology insights to its research partners. The entity currently employs a workforce of 14 individuals and maintains a market capitalization of $4.20M, generating total annual revenue over the trailing twelve months of $142,000. These financial dimensions indicate that VivoSim Labs, Inc. functions as a micro-cap entity with a very small operational footprint, suggesting that its business model relies on high-value, low-volume service contracts rather than mass-market product sales. The combination of a negligible revenue base and a market cap under five million dollars underscores the speculative nature of the investment, where the company's survival and expansion depend entirely on securing a consistent stream of research partnerships in the biotechnology field.
Financiële gezondheid
Over the trailing twelve months, the company reported a revenue of $142,000 alongside a net income of $-1,227,000 and an EBITDA of $-11,221,000, revealing a severe structural disconnect between top-line generation and profitability. The massive gap between the modest revenue figure and the substantial net loss indicates that the company's cost structure is heavily weighted toward research and development expenses or operational overheads that far exceed its current income stream. Free cash flow stands at $-7,895,875, which signifies a significant cash burn rate that limits the company's immediate financial flexibility and necessitates reliance on external capital sources or existing cash reserves to fund operations. The margin profile is equally stark, with a gross margin of 0.0%, an operating margin of -10576.9%, and a profit margin of 0.0%, reflecting that the company is not yet generating a return on its direct production or service costs at a scale that contributes to the bottom line. Regarding liquidity and leverage, the firm holds $4.29M in cash against $812,000 in debt, resulting in a debt-to-equity ratio of 18.28, which suggests a balance sheet that is technically conservative in terms of absolute debt load but leveraged in a manner typical for early-stage biotechs utilizing cash reserves to offset negative equity. The current ratio is reported at 2.44, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities, although the high ratio is driven primarily by the substantial cash position rather than operational efficiency. Return on Equity stands at -51.1% and Return on Assets is -132.5%, metrics that clearly reveal that management has not yet achieved effectiveness in generating positive returns on the capital invested by shareholders or utilized in the company's asset base.
Waarderingsbeoordeling
The valuation metrics present a complex picture due to the absence of traditional earnings-based multiples, with a trailing P/E ratio of 0.82 and a forward P/E ratio listed as N/A, implying that the market is currently pricing the stock without a consensus on future normalized earnings or expecting a turnaround in profitability before standard valuation models become applicable. The price-to-book ratio is 0.85, suggesting that the market values the company at a discount to its net asset value, which may reflect skepticism regarding the recoverability of its intangible assets or the ability to monetize its research models. Alternative valuation metrics such as the price-to-sales ratio of 29.56 and an EV/EBITDA of -0.03 further highlight the speculative valuation, where the market is willing to pay a significant premium relative to sales despite the company's lack of profitability, a common characteristic in the biotechnology sector where future pipeline potential is valued over current financial performance. In terms of price action, the stock has traded between a 52-week low of $1.25 and a 52-week high of $5.30, meaning the current market price sits somewhere within this wide range, reflecting significant volatility and uncertainty surrounding the company's immediate value proposition. The beta value is 1.44, indicating that the stock's price volatility is substantially higher than that of the broader market, exposing investors to greater systematic risk during periods of market turbulence.
Growth & Income
Revenue growth over the year-on-year period stands at 8.3%, while earnings growth is listed as N/A due to the company's continued negative net income, which implies that the company is in a phase of scaling revenue before achieving the profitability necessary to support meaningful earnings expansion. Because the company has not established a history of consistent earnings growth, the lack of a dividend yield and a payout ratio of 0.0% indicates that VivoSim Labs, Inc. does not distribute cash to shareholders but instead retains all available resources, including its $4.29M cash balance, to reinvest into research activities and operational growth. The absence of a dividend policy is consistent with the company's biotechnology status and negative financial performance, as paying dividends would be financially unsustainable given the net loss and negative free cash flow. Overall, the growth and income profile of VivoSim Labs, Inc. is characterized by modest revenue expansion coupled with a complete lack of income distribution, positioning the company as a pure-play growth vehicle dependent on future commercialization or licensing success to unlock shareholder value.